Affinia Therapeutics is enhancing gene therapies by expanding the potential of adeno-associated viruses (AAVs). AAVs are the vectors that target cells and deliver gene therapies. Affinia is using their Affinia Rationally-designed Therapies (ART) platform to improve the efficacy, safety, and manufacturability of AAVs for gene therapies. This involves re-engineering AAVs with improved tissue targeting, finding novel promoters to control gene expression levels, and new cell lines and transfection agents to enhance quality, yields, and scalability. Affinia’s current pipeline is focused on nervous system diseases, including cancers affecting the brain. These diseases are difficult to target due to the blood brain barrier, which Affinia hopes their approach will overcome.

<p>Affinia Therapeutics is enhancing gene therapies by expanding the potential of adeno-associated viruses (AAVs). AAVs are the vectors that target cells and deliver gene therapies. Affinia is using their Affinia Rationally-designed Therapies (ART) platform to improve the efficacy, safety, and manufacturability of AAVs for gene therapies. This involves re-engineering AAVs with improved tissue targeting, finding novel promoters to control gene expression levels, and new cell lines and transfection agents to enhance quality, yields, and scalability. Affinia’s current pipeline is focused on nervous system diseases, including cancers affecting the brain. These diseases are difficult to target due to the blood brain barrier, which Affinia hopes their approach will overcome.</p>


Affinia Therapeutics

Founded: 2019
Location: Waltham, MA
Employee range: 51-100
Clinical stage: RD
Therapy area: Muscle diseases
Drug types: GEN, NEU, MUS, CVV, LNG
Lead product: Undisclosed
Funding: 100-500M

Drug notes:

About:

Jobs: